The agency previously said it will finish reviewing Pfizer's application by January, but full approval could also come before then.
To date, the FDA has not said publicly when it expects to complete the process, but the agency told the network that it was urgently reviewing the drugmakers’ applications.
The FDA also emphasized that the vaccines have already undergone a “thorough scientific evaluation” in order to meet its “rigorous standards for safety, effectiveness, and manufacturing quality.” Full approval will hinge on several months of additional data.The Pfizer and Moderna vaccines were each granted an Emergency Use Authorization from the agency in December, while the Johnson & Johnson shot was granted its EUA in February.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Israel to offer Pfizer booster shots to people over 60Israel will begin offering a third shot of the Pfizer-BioNTech Covid-19 vaccine to people over 60, Israel's Kan public radio and Channel 13 TV say.
Consulte Mais informação »
Citing New Data, Pfizer Outlines Case for Booster ShotsPfizer offered new evidence on Wednesday in support of booster shots of its potent vaccine, reporting that the vaccine’s power wanes slightly over time but may be improved with a third dose. The new data, which have not yet been peer-reviewed nor published in a scientific journal, nonetheless confirm that the two-dose vaccine offers potent protection against the coronavirus. Whether booster shots will be widely needed is far from settled, the subject of heated debate among scientists. So far, fe
Consulte Mais informação »
Pfizer data suggest third dose of Covid-19 vaccine 'strongly' boosts protection against Delta variantA third dose of the Pfizer/BioNTech Covid-19 vaccine can 'strongly' boost protection against the Delta variant -- beyond the protection afforded by the standard two doses, suggests new data released by Pfizer on Wednesday.
Consulte Mais informação »
Pfizer Raises Full-Year Outlook on Covid-19 Vaccine SalesThe pharmaceutical company’s Covid-19 vaccine co-developed with BioNTech contributed $7.8 billion to Pfizer’s total sales of $18.98 billion in the latest quarter.
Consulte Mais informação »
Stocks making the biggest moves premarket: McDonald's, Boeing, Pfizer, Spotify and moreThese are the stocks posting the largest moves before the bell.
Consulte Mais informação »
Pfizer Vaccine Protection Wanes After 6 Months Study FindsPfizer’s COVID-19 vaccine continues to show strong protection against serious illness and hospitalization after 6 months, but overall protection against the virus appears to wane after a half a year, according to a new study.
Consulte Mais informação »